Načítá se...
ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS
Survival benefit of bevacizumab (BEV) could not be confirmed for recurrent glioblastomas in EORTC 26101, while BEV is commonly chosen at recurrence due to its positive effect in daily life. BEV is usually repeated until tumor progression or adverse events, but the benefit of continuation of BEV is n...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216360/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.070 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|